Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Oragenics, Inc. OGEN

Healthcare  —  Biotechnology
0.49 (0.01) (2.00%) as of 25 Sep
Market cap
$2.3M
P/E
0.4×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Oragenics, Inc. (OGEN) Business Profile

Updated before January 2025

Company Overview

Oragenics, Inc. (OGEN) is a biotechnology company focused on the development of innovative therapies to address unmet medical needs. Founded in 1996 and headquartered in Tampa, Florida, Oragenics has carved a niche in the pharmaceutical and biotechnology sectors by leveraging cutting-edge research and development. The company was originally established by Dr. Jeffrey Hillman, a prominent microbiologist, with the aim of advancing oral health solutions. Over the years, Oragenics has expanded its focus to include infectious diseases and other therapeutic areas. The company is led by a team of experienced professionals, including its CEO, Michael Sullivan, who brings extensive expertise in corporate strategy and biotechnology.

Core Business Segments

Infectious Disease Therapies

Oragenics is primarily focused on the development of novel antibiotics and vaccines to combat infectious diseases. The company’s flagship product candidate is OG716, a lantibiotic designed to treat Clostridioides difficile infections (CDI). This innovative therapy is aimed at addressing the growing issue of antibiotic resistance.

SARS-CoV-2 Vaccine Development

In response to the global COVID-19 pandemic, Oragenics has been actively developing a vaccine candidate, Terra CoV-2, which is based on a spike protein antigen licensed from the National Institutes of Health (NIH). This vaccine is designed to provide broad protection against SARS-CoV-2 and its variants.

Oral Health Solutions

Oragenics initially gained recognition for its work in oral health. The company developed ProBiora3, a proprietary blend of probiotics aimed at improving oral health by promoting beneficial bacteria in the mouth. While this segment is no longer the primary focus, it remains a part of the company’s legacy.

Business Model

Oragenics operates as a research-driven biotechnology company, focusing on the development and commercialization of innovative therapies. The company’s business model revolves around:

  1. Research and Development (R&D): Oragenics invests heavily in R&D to create novel therapies. The company collaborates with academic institutions, government agencies, and private organizations to advance its pipeline.
  2. Licensing Agreements: The company licenses key technologies and intellectual property from renowned institutions, such as the NIH, to accelerate product development.
  3. Revenue Generation: While Oragenics is still in the development phase for many of its products, future revenue streams are expected to come from product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.

Strategic Direction

Oragenics is committed to addressing critical healthcare challenges through innovation. The company’s strategic priorities include:

  • Advancing the Development of OG716: Oragenics aims to complete clinical trials and secure regulatory approval for OG716, positioning it as a leading treatment for CDI.
  • Expanding the Terra CoV-2 Vaccine Program: The company is focused on advancing its COVID-19 vaccine candidate through clinical trials and exploring opportunities for global distribution.
  • Exploring New Therapeutic Areas: Oragenics is actively seeking to expand its pipeline by identifying new therapeutic targets and leveraging its expertise in microbiology and immunology.
  • Sustainability Goals: The company is committed to sustainable practices in its operations and product development, ensuring long-term value creation for stakeholders.

Competitive Landscape

Oragenics operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Pfizer and Moderna: These companies dominate the COVID-19 vaccine market, posing significant competition to Oragenics’ Terra CoV-2 program.
  • Merck and Roche: These pharmaceutical giants have a strong presence in the infectious disease space, competing with Oragenics’ antibiotic development efforts.
  • Small Biotech Firms: Companies like Seres Therapeutics and Rebiotix are also developing innovative therapies for CDI, creating a competitive landscape for OG716.

Risk Factors

Oragenics faces several risks that could impact its operations and financial performance:

  • Regulatory Challenges: The company’s products must undergo rigorous clinical trials and obtain regulatory approval, which can be time-consuming and costly.
  • Market Dependence: Oragenics is heavily reliant on the success of its pipeline products, particularly OG716 and Terra CoV-2.
  • Supply Chain Disruptions: The global supply chain for raw materials and manufacturing could impact the company’s ability to produce and distribute its products.
  • Competition: Intense competition from larger pharmaceutical companies and other biotech firms could limit Oragenics’ market share.
  • Financial Constraints: As a development-stage company, Oragenics relies on external funding and may face challenges in securing adequate capital.

Recent Developments

  • Progress in OG716 Development: Oragenics recently announced positive preclinical results for OG716, demonstrating its potential efficacy and safety.
  • Advancements in Terra CoV-2: The company has made significant progress in the development of its COVID-19 vaccine candidate, including preclinical studies and preparations for clinical trials.
  • Partnerships and Collaborations: Oragenics has entered into strategic partnerships with academic institutions and government agencies to accelerate its R&D efforts.
  • Impact of Global Events: The COVID-19 pandemic has underscored the importance of Oragenics’ work in infectious diseases, driving increased interest and investment in the company.

Investment Considerations

Strengths

  • Innovative Pipeline: Oragenics has a robust pipeline of novel therapies targeting unmet medical needs.
  • Experienced Leadership: The company is led by a team of seasoned professionals with expertise in biotechnology and pharmaceuticals.
  • Strategic Partnerships: Collaborations with renowned institutions enhance the company’s R&D capabilities.

Risks

  • Development Stage: As a development-stage company, Oragenics has yet to generate significant revenue from product sales.
  • Regulatory and Market Risks: The success of the company’s products depends on regulatory approval and market acceptance.
  • Financial Uncertainty: The company’s reliance on external funding poses a risk to its long-term sustainability.

Conclusion

Oragenics, Inc. is a promising biotechnology company with a focus on addressing critical healthcare challenges through innovation. While the company faces significant risks, its robust pipeline, strategic partnerships, and experienced leadership position it well for future growth. As Oragenics advances its pipeline products and explores new therapeutic areas, it has the potential to make a meaningful impact in the biotechnology sector and deliver value to its stakeholders.